Phthalates (diesters of phthalic acid) are widely used as plasticizers and additives in many consumer products. Laboratory animal studies have reported the endocrine-disrupting and reproductive effects of phthalates, and human exposure to this class of chemicals is a concern. Several phthalates have been recognized as substances of high concern. Human exposure to phthalates occurs mainly via dietary sources, dermal absorption, and air inhalation. Phthalates are excreted as conjugated monoesters in urine, and some phthalates, such as di-2-ethylhexyl phthalate (DEHP), undergo secondary metabolism, including oxidative transformation, prior to urinary excretion. The occurrence of phthalates and their metabolites in urine, serum, breast milk, and semen has been widely reported. Urine has been the preferred matrix in human biomonitoring studies, and concentrations on the order of several tens to hundreds of nanograms per milliliter have been reported for several phthalate metabolites. Metabolites of diethyl phthalate (DEP), dibutyl- (DBP) and diisobutyl- (DiBP) phthalates, and DEHP were the most abundant compounds measured in urine. Temporal trends in phthalate exposures varied among countries. In the United States (US), DEHP exposure has declined since 2005, whereas DiNP exposure has increased. In China, DEHP exposure has increased since 2000. For many phthalates, exposures in children are higher than those in adults. Human epidemiological studies have shown a significant association between phthalate exposures and adverse reproductive outcomes in women and men, type II diabetes and insulin resistance, overweight/obesity, allergy, and asthma. This review compiles biomonitoring studies of phthalates and exposure doses to assess health risks from phthalate exposures in populations across the globe.

Bisphenol A (BPA) and its alternatives are suspected endocrine disruptors. However, prenatal exposure and transplacental transfer of bisphenols (BPs is still limited. Therefore, BPA and its six alternatives in maternal serum (MS), maternal urine (MU), cord serum (CS), and amniotic fluid (AF) samples collected from 106 maternal-fetal pairs in an e-waste dismantling site in Southern China were determined. Bisphenol AF (BPAF) and bisphenol S (BPS) were the dominant BPA alternatives observed in MS and CS, and the geometric mean (GM) concentration of BPAF (0.013 ng/mL in MS, 0.097 ng/mL in CS) and BPS (0.01 ng/mL in MS, 0.03 ng/mL in CS) in MS and CS was lower than that of BPA (0.5 ng/mL in MS, 1.2 ng/mL in CS). The ratios of BPA concentrations between MU and MS (MU:MS ratio) were over three times higher than those of AF and CS (AF:CS ratio), thereby suggesting low biotransformation/metabolism of BPA in fetuses. The placental transfer rates of BPs (i.e., CS:MS ratio) were compound-specific (BPAF 3.26, BPA 1.94, BPS 1.11). Results suggest that BPA and its alternatives can pass through the placental barrier. The placental transfer rates of BPs are positively related to molecular weight or log Kow values. This finding indicates that an active transport is responsible for the placental transfer of BPs.

Organophosphate esters (OPEs) are used in consumer products as flame retardants and plasticizers. Little is known, however, about the occurrence and profiles of OPEs in human milk. In this study, 14 OPEs were measured in 100 breast milk samples collected from the United States during the period of 2009–2012, using high-performance liquid chromatography and tandem mass spectrometry. The sum concentrations of 14 OPEs in human milk ranged from 0.670 to 7.83 ng/mL, with a mean value of 3.61 ng/mL. The highest mean concentration was found for tris-2-butoxyethyl phosphate (TBOEP, 1.44 ± 0.789 ng/mL), followed by tri-iso-butyl phosphate (TIBP, 0.569 ± 0.272 ng/mL) and tri-n-butyl phosphate (TNBP, 0.539 ± 0.265 ng/mL), which were the dominant OPEs found in breast milk at detection frequencies of >80%. No significant differences were observed between various maternal/infant characteristics and OPE concentrations (p > 0.05), except for TBOEP, for which the median concentrations in Hispanic mothers (0.765 ng/mL) were 2 times lower than those in non-Hispanic mothers (1.48 ng/mL) (p < 0.05). On the basis of the recommended daily milk ingestion rate, the average and the highest daily intakes of total OPEs were calculated to be in the range of 300–542 and 504–911 ng (kg of body weight)⁻¹ day^–1, respectively. The estimated daily intakes of OPEs did not exceed the current reference doses. Our study establishes baseline data for OPE exposure in breast-fed American children.